Biotech Sector’s Hot Stocks in the News – PATH, ARNA, ACAD, AMGN.
NEW YORK, JANUARY 23, 2013 — (Net PR News) – NuPathe Inc (NASDAQ:PATH) reported that the U.S. Food and Drug Administration (FDA) has approved the treatment of migraines in adults, the treatment is named Zecuity™ (sumatriptan iontophoretic transdermal system).
NuPathe Inc remained a bull for the day as it reported the gain of 8.48% and closed at $3.58 after gaining total volume of 3.01 million shares.
Is PATH A Solid Investment At These Levels? Find Out Exactly Where PATH Is Headed With This TREND ANALYSIS REPORT
PATH has the total of 14.75 million outstanding shares and its total market capitalization is $52.82 million.
The Company’s year to date performance remained quite optimistic with the gain of 5.92%, while in the last 6 months it slipped almost -6.04%. During the last three months the company reported an upward momentum of 0.02%.
Another biotech company which was moving down during the previous trade was Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). It ended its day with the losing stream and lost-9.72%. Its shares closed at the price of $8.82, after opening at $9.06. Stock traded during its last trading session with the total volume of 26.84 million shares, as compared to its average volume of 10.03 million shares.
Get A Free Report And Detailed Analysis On ARNA CLICK HERE To Read
During the previous session, the company’s minimum price was $8.70 while it touched its highest price for the day at $9.24. ARNA’s beta value stands at 0.24 points. During the last one month, the company surged 2.2% while its last 5 days shows a drop of -13.54%.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) reported that it has elected Stephen R. Biggar, M.D., Ph.D., as member of its Board of Directors. Mr.Stephen R. Biggar will serve as a Class II director. The company also reported that the terms of Class II directors will finish in 2015, at the annual meeting of stockholders.
ACADIA Pharmaceuticals opened at the price of $5.23, whereas its previous closing price was recorded at $5.67. ACAD gained 8.62% and traded within the range of $5.16 – $5.74 for the day. The 52week range of the stock remained in between $1.29 – $6.53. Total volume of the stock was 2.33 million shares during last trade, while its average volume is 2.19 million shares.
How Should Investors React To ACAD Now? Find Out In This TREND ANALYSIS REPORT
The Company’s total market capitalization stands at $338.25 million, along with 59.66 million outstanding shares.
Amgen, Inc. (NASDAQ:AMGN) reported the increase of +1.47%, to close at $83.29, with the overall traded volume of 9.39 million shares.
Amgen, Inc. (NASDAQ:AMGN) has the total of 767.36 million outstanding shares. During last trade, the company’s minimum price was $81.56 while it touched its highest price of $83.41.
Its market capitalization was $63.91 billion. Its beta value stands at 0.40 times and earning per share was $5.59.
The Company’s year to date performance remained pessimistic with the drop of -3.38%. If we look at last its 6 months of trade, it is in the bullish zone with the upsurge of 7.1%.
How Should Investors Trade AMGN Now? Don’t Trade AMGN Until You Read This TREND ANALYSIS REPORT
About Fast Moving Stocks
FastMovingStock.com is engaged in providing valuable ideas and news information on U.S. stocks on a regular basis. FastMovingStock.com provides detailed research guides on small cap and large cap stocks, helping investors in making wise stock market investment decisions through its free e-newsletter to subscribers.
The assembled information disseminated by fastmovingstock.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Fast moving stock.com does not expect that investors will buy and sell securities based on information assembled and presented in fastmovingstock.com. PLEASE always do your own due diligence, and consult your financial advisor.